Article
Genotype-guided dosing of coumarin derivatives: the European pharmacogenetics of anticoagulant therapy (EU-PACT) trial design.
Pharmacogenomics - 1 Oct 2009
van Schie Rianne M F, Wadelius M I A, Kamali Farhad, Daly Ann K, Manolopoulos Vangelis G, de Boer Anthonius, Barallon Rita, Verhoef Talitha I, Kirchheiner Julia, Haschke-Becher Elisabeth, Briz Montserrat, Rosendaal Frits R, Redekop William K, Pirmohamed Munir, Maitland van der Zee Anke-Hilse
Abstract excerpt
The narrow therapeutic range and wide interpatient variability in dose requirement make anticoagulation response to coumarin derivatives unpredictable. As a result, patients require frequent monitoring to avert adverse effects and maintain therapeutic efficacy. Polymorphisms in VKORC1 and CYP2C9 jointly account for about 40% of the interindividual variability in dose requirements. To date, several...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.